RxDoctor Payments Data

Warren Hankins

Lake Havasu City, AZNPI 1881648293

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $133,359 of the $135,645 with a category attached, or 98.3%. AbbVie accounts for 98.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $118,054 and has fallen 99.7% since, to $349 in 2025.

$135,645in general payments, 2019–2025

Across 115 payments — averaging $1179.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$134K
  • Mentor Worldwide LLC$1K
  • Merz North America, Inc.$391
  • Sientra, Inc.$317
  • Galderma Laboratories, L.p.$127
  • Boston Scientific$17
  • plus $7 from 1 others
$151,356in research payments, 2019–2025

Across 25 payments — averaging $6054.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mentor Worldwide LLC$114K
  • Medical Device Business Services, Inc.$38K

What the payments were for

  • Speaking & faculty fees$133,35998%
  • Food & beverage$2,2772%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$91
Cephalexin16$78

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →